Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E Cellular energy depletion and secondary oxidative injury are present early, even presymptomatically in Huntington's disease (HD), and play a significant role in its pathogenesis. Creatine is an inexpensive and well-tolerated nutritional supplement that is converted in the body to phosphocreatine that acts as a high- energy phosphate store for restoring ATP from ADP. We have extensively shown creatine to delay the onset and slow the progression of the pathologic phenotypes in HD transgenic and knockin mice in a dose dependent manner and to correct their ATP deficiencies in brain. In our double-blind placebo-controlled study of 8 grams per day of creatine for 16 weeks in HD patients, we demonstrated that creatine is safe and tolerable, increases serum and brain levels of creatine, and markedly reduces a serum biomarker of oxidative injury to DNA (8OH2'dG) suggesting beneficial effects on a fundamental mechanism of pathogenesis in HD. We subsequently completed an open-label dose escalation study pushing creatine up to 40 grams daily. We found 30 grams daily to be the optimal dose based on serum and brain bioavailability, reduced tolerability at higher doses, dose dependent suppression of 8OH2'dG levels, evidence for slowed cognitive decline, and a sustained reduction in brain atrophy as determined by MRI morphometry. We now propose a multi-center, randomized, double-blind, placebo-controlled trial of 30 grams daily creatine in 650 symptomatic individuals with HD recruited from about 42 Huntington Study Group (HSG) sites, treated for 36 months to test the hypothesis that it will slow the progressive functional decline of HD. Our secondary clinical aims are to assess safety and tolerability by analyzing clinical and laboratory adverse events and to assess the clinical impact of creatine on impressions of global health (CGI), quality of life measures (SF-36), and on motor, cognitive, psychiatric, behavioral, and functional symptoms of HD. We also propose collaborating with a program project on HD biomarkers to provide additional secondary endpoints and to exploit this first opportunity to assess and validate particular biomarkers in a large prospective HD clinical trial. We have conceived a design incorporating interim analyses of safety, futility, and efficacy that would provide early and repeated safety data and also permit early stopping or modification. A companion application is also submitted to support study coordination, data management, and biostatistical support under the auspices of the HSG (Bernard Ravina, principal investigator).

National Institute of Health (NIH)
National Center for Complementary & Alternative Medicine (NCCAM)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Program Officer
Pontzer, Carol H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Santiago, Jose A; Scherzer, Clemens R; Potashkin, Judith A (2014) Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. PLoS One 9:e109042
Kim, Jinho; Amante, Daniel J; Moody, Jennifer P et al. (2010) Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim Biophys Acta 1802:673-81
Iverson, D J; Gronseth, G S; Reger, M A et al. (2010) Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74:1316-24
Mainero, Caterina; Benner, T; Radding, A et al. (2009) In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 73:941-8
Rosas, H Diana; Salat, David H; Lee, Stephanie Y et al. (2008) Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann N Y Acad Sci 1147:196-205
Hersch, Steven M; Rosas, H Diana (2008) Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 5:226-36
Rosas, H Diana; Salat, David H; Lee, Stephanie Y et al. (2008) Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 131:1057-68
Klein, Autumn M; Ferrante, Robert J (2007) The neuroprotective role of creatine. Subcell Biochem 46:205-43
Fox, Jonathan H; Kama, Jibrin A; Lieberman, Gregory et al. (2007) Mechanisms of copper ion mediated Huntington's disease progression. PLoS One 2:e334
Kazantsev, Aleksey G; Hersch, Steven M (2007) Drug targeting of dysregulated transcription in Huntington's disease. Prog Neurobiol 83:249-59

Showing the most recent 10 out of 11 publications